Cancer Cells' Own Gas Used for New Treatment

A groundbreaking approach to cancer treatment leverages carbon monoxide, a metabolic byproduct found in abundance within cancer cells. Researchers have developed a method involving palladium-containing compounds, known as palladacycles, to activate this internal carbon monoxide. These palladacycles are encased in albumin, a blood protein, to shield them from natural cellular defenses. This shielding mechanism allows the palladacycles to enter cells undetected, where they react with the excess carbon monoxide to generate phenanthridinone. Phenanthridinone is a compound already recognized for its efficacy in certain cancer treatments.

Initial testing on human liver, breast, and lung cancer cells, as well as cancer-free cells, demonstrated a significant finding. After 48 hours, phenanthridinone was detected only in the cancerous cells, indicating a selective targeting capability. This selectivity is attributed to the higher concentration of carbon monoxide present in malignant cells compared to healthy cells. Further refinement of the palladacycles enhanced their toxicity specifically towards cancer cells. Studies suggest that existing carbon monoxide in healthy blood does not prematurely trigger this reaction due to its binding with hemoglobin.

The next phase of research involves testing this innovative treatment in animal models to assess its real-world efficacy, determine appropriate dosages, and understand its systemic effects. This preclinical stage is crucial before considering human trials.